Natera (NASDAQ:NTRA) Stock Price Down 8.7% – What’s Next?

Shares of Natera, Inc. (NASDAQ:NTRA) fell 8.7% on Friday . The stock traded as low as $196.22 and last traded at $197.1930. 610,194 shares changed hands during trading, a decline of 45% from the average session volume of 1,107,863 shares. The stock had previously closed at $216.10.

Natera News Roundup

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Quarterly beat — Natera reported Q4 revenue of $665.5M and GAAP EPS of $0.35, well ahead of street estimates (revenue ~$600.7M, EPS loss consensus). The beat supports near-term growth expectations and underpins the stock’s recent strength. Natera Reports Fourth Quarter and Full Year 2025 Financial Results
• Positive Sentiment: Favorable clinical data — New Signatera MRD data presented at ASCO GU highlight potential utility across genitourinary cancers (including bladder preservation), which may expand clinical adoption and long-term revenue for Natera’s oncology franchise. Signatera MRD Data at ASCO GU
• Positive Sentiment: Trial results — Natera reported results from the SINERGY trial, another clinical datapoint that could support commercial adoption of its assays. Natera Announces Results From the SINERGY Trial
• Positive Sentiment: Analyst upgrades/targets — Robert W. Baird raised its price target to $257 (outperform) and Wells Fargo raised its target to $215 (equal weight), signaling some sell-side confidence in upside from current levels. Benzinga – Analyst Price Target Changes
• Neutral Sentiment: Full-year revenue guidance roughly in line with consensus — Management issued FY2026 revenue guidance (roughly $2.6B–$2.7B), which appears consistent with street expectations and reduces upside surprise potential from guidance alone. (See Q4 release for guidance details.) Natera Reports Fourth Quarter and Full Year 2025 Financial Results
• Neutral Sentiment: Analyst consensus — Aggregated analyst coverage remains constructive (average “Moderate Buy”), which supports medium-term expectations but doesn’t preclude short-term volatility. Analyst Average Rating
• Negative Sentiment: Valuation and fundamentals concerns — Despite the beat, Natera still shows negative net margin and negative return on equity on a GAAP basis; combined with a high market capitalization and a recent run-up toward 52-week highs, investors may be taking profits. MarketBeat Q4 Coverage
• Negative Sentiment: Heavy intraday volume and selling pressure — Trading volume was well above average, consistent with a distribution day where some holders trimmed positions after the company’s strong quarter; that drove the stock lower despite the positives. (See intraday volume and price action for context.)

Analyst Ratings Changes

A number of research analysts have recently commented on NTRA shares. UBS Group increased their target price on shares of Natera from $218.00 to $280.00 and gave the stock a “buy” rating in a report on Tuesday, November 18th. Barclays upped their price objective on shares of Natera from $230.00 to $270.00 and gave the stock an “overweight” rating in a research report on Monday, December 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Natera in a research report on Thursday, January 22nd. TD Cowen reaffirmed a “buy” rating on shares of Natera in a research note on Wednesday, January 7th. Finally, Canaccord Genuity Group reiterated a “buy” rating on shares of Natera in a research note on Monday, January 12th. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $254.47.

Natera Stock Down 3.7%

The stock has a market cap of $28.78 billion, a P/E ratio of -135.97 and a beta of 1.64. The company’s 50 day moving average price is $226.52 and its 200-day moving average price is $203.85.

Natera (NASDAQ:NTRA) last posted its quarterly earnings data on Thursday, February 26th. The medical research company reported $0.35 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.81. The business had revenue of $665.50 million during the quarter, compared to the consensus estimate of $600.68 million. Natera had a negative return on equity of 16.71% and a negative net margin of 9.03%.During the same period in the prior year, the business posted ($0.41) earnings per share. Equities research analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current year.

Insider Activity at Natera

In related news, CEO Steven Leonard Chapman sold 85,299 shares of the company’s stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $230.72, for a total value of $19,680,185.28. Following the sale, the chief executive officer directly owned 127,881 shares in the company, valued at $29,504,704.32. This represents a 40.01% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider John Fesko sold 17,806 shares of the stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $234.74, for a total transaction of $4,179,780.44. Following the sale, the insider directly owned 177,591 shares of the company’s stock, valued at $41,687,711.34. This represents a 9.11% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 368,119 shares of company stock valued at $85,956,782 over the last ninety days. Insiders own 5.63% of the company’s stock.

Hedge Funds Weigh In On Natera

Several hedge funds and other institutional investors have recently bought and sold shares of NTRA. Horizon Investments LLC grew its holdings in Natera by 22.0% during the 4th quarter. Horizon Investments LLC now owns 244 shares of the medical research company’s stock worth $56,000 after acquiring an additional 44 shares during the period. Sound Income Strategies LLC boosted its position in shares of Natera by 20.0% during the 4th quarter. Sound Income Strategies LLC now owns 270 shares of the medical research company’s stock valued at $62,000 after purchasing an additional 45 shares in the last quarter. Savvy Advisors Inc. grew its stake in Natera by 3.1% during the fourth quarter. Savvy Advisors Inc. now owns 1,541 shares of the medical research company’s stock worth $353,000 after purchasing an additional 46 shares during the period. Siemens Fonds Invest GmbH increased its holdings in Natera by 3.1% in the third quarter. Siemens Fonds Invest GmbH now owns 1,804 shares of the medical research company’s stock worth $290,000 after purchasing an additional 54 shares in the last quarter. Finally, Alamea Verwaltungs GmbH lifted its stake in Natera by 2.9% in the fourth quarter. Alamea Verwaltungs GmbH now owns 2,229 shares of the medical research company’s stock valued at $515,000 after buying an additional 62 shares during the period. Institutional investors and hedge funds own 99.90% of the company’s stock.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.